2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

Department of Pharmaceutical Chemistry I, University of Regensburg, D-93040 Regensburg, Germany.
Journal of Medicinal Chemistry (Impact Factor: 5.61). 10/2007; 50(18):4405-18. DOI: 10.1021/jm0703136
Source: PubMed

ABSTRACT Histone deacetylase (HDAC) inhibitors are considered to be drugs for targeted cancer therapy and second-generation HDIs are currently being tested in clinical trials. Here, we report on the synthesis and biological evaluation of a novel HDAC inhibitor scaffold with the hydroxamate Zn(2+) complexing headgroup, selected from the 2-aroylindol motif. Inhibition of nuclear extract HDAC and recombinant HDAC 1 as well as induction of histone H3K(9+14) hyperacetylation mediated by E-N-hydroxy-(2-aroylindole)acrylamides or E-N-hydroxy-(2-aroylbenzofuran)acrylamides were studied. Moreover, the cytotoxic activity, the effects on the cell cycle, and histone H3S(10) phosphorylation of selected compounds were determined. By use of a panel of 24 different human tumor cell lines, mean IC(50) values of the most potent analogues 6c and 7b were 0.75 and 0.65 microM, respectively. The novel compounds were shown to be no substrates of the P-glycoprotein drug transporter. Comparable to N(1)-hydroxy-N(8)-phenyloctanediamide "2 (SAHA)", cells in the S phase of the cell cycle are depleted, with partial arrest in G1 and G2/M and finally induction of massive apoptosis.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper describes the first efficient one-step synthesis of 2-aroylbenzofuran-3-ols from the microwave-assisted Dieckmann reaction of substituted methylsalicylates with 2-bromo-1-aroylethanones in alkaline aprotic solvents. This method features excellent yields, short reaction time (15 min) and high functional group compatibility, making it an efficient and practical approach for the synthesis of 2-aroylbenzofuran-3-ols.
    Advanced Synthesis & Catalysis 10/2010; · 5.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple procedure for the synthesis of 2-aroylindole derivatives comprising a one-pot CuI-catalyzed SNAr reaction of o-bromochalcones with sodium azide and subsequent intramolecular cyclization through nitrene C-H insertion has been developed. This protocol is also applicable with the 2'-bromocinnamates giving the indole-2-carboxylates.
    ChemInform 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In addition to being a part of the metabolic fatty acid fuel cycle, butyrate is also capable of inducing growth arrest in a variety of normal cell types and senescence-like phenotypes in gynecological cancer cells, inhibiting DNA synthesis and cell growth in colonic tumor cell lines, suppressing hTERT mRNA expression and telomerase activity in human prostate cancer cells, and inducing stem cell differentiation and apoptosis by DNA fragmentation. It regulates gene expression by inhibiting histone deacetylases (HDACs), enhances memory recovery and formation in mice, stimulates neurogenesis in the ischemic brain, promotes osteoblast formation, selectively blocks cell replication in transformed cells (compared to healthy cells), and can prevent and treat diet-induced obesity and insulin resistance in mouse models of obesity, as well as stimulate fetal hemoglobin expression in individuals with hematologic diseases such as the thalassemias and sickle-cell disease, in addition to a multitude of other biochemical effects in vivo. However, efforts to exploit the potential of butyrate in the clinical treatment of cancer and other medical disorders are thwarted by its poor pharmacological properties (short half-life and first-pass hepatic clearance) and the multigram doses needed to achieve therapeutic concentrations in vivo. Herein, we review some of the methods used to overcome these difficulties with an emphasis on HDAC inhibition.
    BioResearch open access. 08/2012; 1(4):192-8.